NIA Small Business Showcase: Newomics, Inc.
Alzheimer’s disease (AD) is a devastating neurodegenerative disease that affects millions of people worldwide, including more than 5.5 million Americans, and this number is expected to increase significantly. There is currently no blood-based biomarker for early diagnosis or target therapy of AD. The field is calling for transformative technologies and approaches.
Newomics developed the integrated silicon microfluidic chips as a high-throughput and multiplex platform for liquid chromatography–mass spectrometry (LC-MS)–based multiomics assays. The company’s M3 emitter product line enables unprecedented gains in sensitivity, throughput, and robustness for LC-MS. The multinozzle emitter array (MEA) technology will be applied to develop multiomics diagnostic assays for AD—as well as diabetes and other diseases—in collaboration with leading AD-focused academic institutes.
Given that AD affects millions of people worldwide, the global market for AD diagnostics is projected to attain revenues of more than $12 billion.
The Newomics platforms and solutions, which include both integrated mass spectrometry (MS) front-end solutions to enable small-volume multiomics analysis of biological samples and extremely sensitive, clog-resistant devices for faster, more accurate, and reproducible biospecimen analysis, will accelerate precision medicine. The tools will enable rapid, low-cost, reproducible, highly specific, and sensitive multiplex measurements of human peripheral blood and cerebrospinal fluid samples. The tools and assays will help in both the diagnosis of AD and the discovery of antibodies for treating the disease.
- 2019: Global launch of the first product MS interface to increase the sensitivity and robustness of LC-MS–based diagnostics
- 2019: Patent on disease diagnosis granted
- 2020: Patent on biomonitoring granted
- 2020: U.S. Department of Energy (DOE) announcement of the Newomics multinozzle (M3) emitter as one of the top innovations in medical technology in the last 75 years from 17 national DOE labs
- 2020–2021: Launch of several new products from the deep product pipeline for a variety of diseases
Newomics has raised $12 million in nondilutive NIH grants since its inception and received $3.9 million in Series A funding from venture capital firms in 2018. The company expects to raise Series B funding for commercialization and scale-up.
Newomics has five issued U.S. patents, with three licensed exclusively from the University of California/Lawrence Berkeley National Laboratory and two filed and owned by the company.
Product Development and Regulatory Strategy
The first product, the M3 emitter, is on the market; the second, the microflow LC-nanospray electrospray ionization MS platform (MnESI-LC-MS) source, is in beta testing; and a third, the MEA chip, is in alpha testing. Various clinical diagnostics are at the research and development (R&D) stage. In due course, the company will pursue International Organization for Standardization, Clinical Laboratory Improvement Amendments, and U.S. Food and Drug Administration regulatory approvals.
Newomics provides MS front-end solutions, including interface and consumables for biopharmaceutical, environmental monitoring, forensic, and clinical R&D, and collaborates and co-markets with major MS vendors and other partners, including Thermo Fisher Scientific, Bruker Corporation, SCIEX, and Waters Corporation. The company already has more than 66 customers from R&D laboratories in leading institutions, including Biogen, Genentech, Merck, Regeneron Pharmaceuticals, and the Centers for Disease Control and Prevention. Newomics will use its own platform to automatize its approach to enable precision medicine.
804 Heinz Avenue, Suite 150
Berkeley, CA 94710
- Founder and CEO: Daojing Wang, Ph.D.
- Co-Founder and Director of Product Engineering: Pan Mao, Ph.D.
Point of Contact:
Daojing Wang, Ph.D.
Email Daojing Wang
Conference Selected for Showcase: BIO Digital (June 2020)